Refine by
Drugs Design Suppliers Serving Belgium
52 companies found
based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic ...
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
based inStanmore, UNITED KINGDOM
Acellera’s mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. In order to fulfill this vision, we work with our customers by becoming a key technology partner, boosting their ...
based inCambridgeshire, UNITED KINGDOM
Computational, medicinal and synthetic chemists from the world’s leading research organizations use our software on a daily basis. Our customers include 8 out of the top 10 pharmaceutical companies. Beyond pharmaceuticals you will find Cresset ...
A single platform for ligand-based and structure-based drug design that enables research chemists to discover novel small molecules more efficiently and ...
based inNY, NEW YORK (USA)
As a global Contract Research Organization (CRO), headquartered in New York, USA, Alfa Chemistry has served the pharmaceutical and biotechnology industries for years. Today, Alfa Chemistry is specialized in organic chemistry, material chemistry, and ...
Introducing fluorine atom(s) into bioactive organic compounds has become a leading strategy for drug design and lead optimization. In drug synthesis strategy, fluorine is frequently employed to ...
based inTel-Aviv, ISRAEL
RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on our promises, to build a company at the forefront of ...
Opaganib (ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral ...
based inPak Shek Kok, HONG KONG
Artificial intelligence for every step of pharmaceutical research and development. Our mission is to accelerate drug discovery and drug development by continuously inventing and deploying new artificial intelligence technologies. We provide AI ...
Chemistry42 is an automated machine learning platform for drug design capable of finding novel lead-like structures in ...
based inStockholm, SWEDEN
IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. IBT is currently developing its ...
IBP-9414 for the prevention of necrotizing enterocolitis (NEC) contains the active substance Lactobacillus reuteri, which is a co-evolved human bacterial strain naturally present in breast milk. Lactobacillus reuteri is a live bacteria known to be ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
![Ibio - Model 100 - Idiopathic Pulmonary Fibrosis [IPF] Therapeutics](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzEyNTA4Ny9wcm9kdWN0cy84NTMxMzQvMTI1MDg3XzJfMjAyMzAyMTMwNjEwNTM5ODQxNzI5X3Jhdy5wbmciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MTQzLCJoZWlnaHQiOjEwMn19fQ== "Ibio - Model 100 - Idiopathic Pulmonary Fibrosis [IPF] Therapeutics")
Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased scarring leads to decreasing transfer of oxygen into the bloodstream, and ultimately, ...
based inStockholm, SWEDEN
Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and increase blood flow in the body’s microvasculature, thereby providing safe and efficacious treatments for several ...
based inBasel, SWITZERLAND
EsoCap’s vision is to improve the lives of patients affected by esophageal diseases. The esophagus is a particularly challenging environment, as swallowed drugs only remain in the area between the mouth and the stomach for a few seconds. EsoCap, a ...
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
based inSchlieren, SWITZERLAND
We are an innovative, Swiss life-science Company aiming to provide patients that suffer from large and deep skin defects with the first automate-produced, personalized skin tissue therapy, denovoSkin“ a safe, effective and accessible therapy for ...
To bio-engineer denovoSkin™, a small biopsy of healthy skin is harvested from the patient. The biopsy is processed to isolate epidermal and dermal cells. The cells are expanded in vitro, and thereafter used in combination with a hydrogel to ...
based inOceanside, CALIFORNIA (USA)
Eidogen-Sertanty is dedicated to improving health, medicine, and general well-being. For the last 20-years, Eidogen-Sertanty has helped to expedite the discovery and development of many new, safer medicines through collaborative project team ...
based inParis, FRANCE
Iktos was founded in 2016 by Quentin Perron, Nicolas Do Huu, and Yann Gaston-Mathé, with the aim of developing an innovative and user-friendly technology platform for deep-learning based de novo drug design, leveraging a proprietary algorithm ...
Makya is the first user-friendly SaaS platform for AI-driven de novo drug design focused on Multi-Parametric Optimization ...
based in, NEW YORK (USA)
'Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug ...
based inCarlton, AUSTRALIA
Radiopharm Theranostics has the ambition to become a recognised leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. There is unique potential of ...
DUNP19 is the invention of Professor Ulmert at UCLA. ...
based inIthaca, NEW YORK (USA)
MiTeGen designs, manufactures and distributes products for cryo-em (cryo electron microscopy), crystallization, crystallography and X-ray diffraction of proteins, viruses and small molecule/inorganic compounds, and for manipulation and measurement ...
based inBeaverton, OREGON (USA)
Lumencor provides innovative light engine solutions tailored for a variety of advanced imaging applications within the scientific and industrial communities. Their portfolio includes products such as the ZIVA Light Engine, which integrates ...
based inNanjing, CHINA
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D process and commercial production. Its core businesses include a rationally designed building ...
Virtual screening is a computational approach used to search libraries of small molecules in order to identify hit and even lead compounds. Because of its significantly lower cost, shorter turnaround time, and particularly access to libraries with ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and ...